nach oben

American Journal of Clinical Dermatology

Erschienen in:

01.05.2000 | Disease Management

Management of Androgenetic Alopecia

verfasst von: Chantal Bolduc, Dr Jerry Shapiro

Erschienen in: American Journal of Clinical Dermatology | Ausgabe 3/2000

Einloggen, um Zugang zu erhalten

Abstract

Androgenetic alopecia is by far the most common cause of hair loss. It affects approximately 50% of men by the age of 50 and 20 to 53% of women by the age 50. Although it is a medically benign condition, it is a significant psychosocial issue for many patients. Various different treatment options are now available for androgenetic alopecia.

The best treatment option for women with androgenetic alopecia Ludwig stage I and II is minoxidil 5% solution. If it is not effective after 1 year, antiandrogens can be tried, but there are no large studies showing their efficacy and they have considerable adverse effects. Also, for patients with alopecia that is unresponsive to treatment or with Ludwig stage III, hair transplantation can be offered if the occipital donor area is sufficient. For men, we always offer minoxidil or finasteride therapy and leave the choice of therapy to the patient. Some patients may prefer a systemic agent, whereas others may favor a topical agent. If the condition is not stabilized after 1 year or if the patient wants greater hair density, hair transplantation can be discussed.

There have been tremendous advances in the treatment of hair loss in recent years and the future is very encouraging. As our knowledge of androgenetic alopecia pathophysiology increases, novel targeted treatments will potentially be developed.

Price V.H. Treatment of hair loss. N Engl J Med 1999; 23: 341 (13): 964–1773

Hamilton J.B. Patterned loss of hair in man: types and incidence. Ann N Y Acad Sci 1951; 53: 708–728PubMedCrossRef

Olsen E. Androgenetic alopecia. In: Olsen E., editor. Disorders of hair growth. New York: McGraw-Hill, 1994: 257

Whiting D.A. The diagnosis of alopecia. Current concepts. Kalamazoo (MO); Upjohn Company, 1990

Rhodes T., Girman C.J., Savin R.C., et al. Prevalence of male pattern hair loss in 18–49 year old men. Dermatol Surg 1988: Dec; 24 (12): 1330–1332

Cash T.F. The psychosocial consequences of androgenetic alopecia: a review of the research literature. Br J Dermatol 1999 Sep; 141 (3): 398–405PubMedCrossRef

Randall V. The use of dermal papilla cells in studies of normal and abnormal hair follicle biology. Dermatol Clin 1996; 14 (4): 585–594PubMedCrossRef

Ziller C. Pattern formation in neural crest derivatives. In: Van Neste D., Randall V., editors. Hair research for the next millenium. Amsterdam: Elsevier Science, 1996: 1

Uno H., Cappas A., Schlagel C. Cyclic dynamics of hair follicles and the effect of minoxidil on the bald scalps of the stumptailed macaques. Am J Dermatopathol1985; 7(3): 283–297CrossRef

10.

Shapiro J., Price V.H. Hair regrowth: therapeutic agents. Dermatol Clin 1998; 16 (2): 341–356PubMedCrossRef

11.

Bergfeld W.F. Androgenetic alopecia: an autosomal dominant disorder. Am J Med 1995; 98 (1A Suppl.): 95S–98SPubMedCrossRef

12.

Kuster W., Happle R. The inheritance of common baldness: two B or not two B? J Am Acad Dermatol 1984: 11 (5 Pt 1): 921–926PubMedCrossRef

13.

Norwood O.T. Male pattern baldness: classification and incidence. South Med J 1975; 68: 1359–1365PubMedCrossRef

14.

Chen W., Zouboulis C., Orfanos C. The 5 alpha-reductase system and its inhibitors. Recent development and its perspective in treating androgen-dependent skin disorders.Dermatology 1996; 193: 177–184PubMedCrossRef

15.

Sawaya M.E., Price V.H. Different levels of 5 alpha reductase type I and II, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia. J Invest Dermatol 1997; 109: 296–300PubMedCrossRef

16.

Bingham K., Shaw D. The metabolism of testosterone by human male scalp skin.J Endocrinol 1973; 57: 111–121PubMedCrossRef

17.

Itami S., Kurata S., Sonoda T., et al. Mechanism of action of androgen in dermal papilla cells. Ann N Y Acad Sci 1991; 642: 385–395PubMedCrossRef

18.

Itami S., Kurata S., Sonoda T., et al. Characterization of 5 alpha reductase in cultured human dermal papilla cells from beard and occipital hair. J Invest Dermatol 1991; 96: 57–60PubMedCrossRef

19.

Imperato-McGinley J., Guerrero L., Gautier T., et al. Steroid 5 alpha reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science 1974; 186: 1213PubMedCrossRef

20.

Imperato-McGinley J. 5 alpha reductase deficiency. Curr Ther Endocrinol Metab1994; 5: 351–354

21.

Price V.H. Testosterone metabolism in the skin: a review of its function in androgenetic alopecia, acne vulgaris, and idiopathic hirsutism including recent studies with antiandrogens. Arch Dermatol 1975; 111: 1496–1502PubMedCrossRef

22.

Sawaya M.E., Price V.H., Harris K. Human hair follicle aromatase activity in females with androgenetic alopecia [abstract]. J Invest Dermatol 1990; 94: 575

23.

Randall V.A., Thornton M.J., Messenger A. Cultured dermal papilla cells from androgen-dependent human hair follicles contain more androgen receptors than those from non-balding areas of scalp. J Endocrinol 1992; 133: 141PubMedCrossRef

24.

Sawaya M.E. Purification of androgen receptors in human sebocytes and hair. J Invest Dermatol 1992; 98 (6 Suppl.): 92S–96SPubMedCrossRef

25.

Price V.H., Menefee E. Quantitative estimation of hair growth: comparative changes in weight and hair count with 5% and 2% minoxidil, placebo and no treatment.In: Van Neste D., Randall V., editors. Hair research for the next millenium. Amsterdam: Elsevier Science, 1996: 67

26.

Sawaya M.E. Novel agents for the treatment of Alopecia. Seminars in Cutaneous Medicine and Surgery 1998; 17 (4): 276–283PubMedCrossRef

27.

Baden H., Kubilus J. Effect of minoxidil on cultured keratinocytes. J Invest Dermatol 1983; 81: 558–560PubMedCrossRef

28.

Kiesewetter F., Langer P., Schell H. Minoxidil stimulates mouse vibrissae follicles in organ culture [letter]. J Invest Dermatol 1991; 96: 295–296PubMedCrossRef

29.

Ohtsuyama M., Morhashi M. Minoxidil sulfate effect of internal calcium of cell in the epidermis and epidermal appendages. In: Van neste D., Randall V., editors. Hair research a for the next millenium. Amsterdam: Elsevier Science, 1996: 481

30.

Buhl A. Minoxidil’s action in hair follicles. J Invest Dermatol 1991; 96: 73S–74SPubMedCrossRef

31.

Buhl A., Waldon D., Kawabe T., et al. Minoxidil stimulates mouse vibrissae follicles in organ culture. J Invest Dermatol 1985; 84: 358–420

32.

Philpott M., Sanders D., Kealy T. Whole follicular culture. Dermatol Clin 1996; 14: 595–607PubMedCrossRef

33.

Price V.H., Menefee E., Strauss P.C. Changes in hair weight and hair count in men with androgenetic alopecia, after application of 5% and 2% topical minoxidil, placebo, or no treatment. J Am Acad Dermatol 1999; 41 (5): 717–721PubMedCrossRef

34.

Olsen E. Treatment of androgenetic alopecia with topical minoxidil. Resid Staff Physician 1989; 35: 53

35.

Olsen E., Weiner M.S., Amara I., et al. Five year follow of men with androgenetic alopecia treated with topical minoxidil. J Am Acad Dermatol 1990; 22: 643–646PubMedCrossRef

36.

Olsen E., DeLong E., Weiner M. Long-term follow-up of men with male pattern baldness treated with topical minoxidil. J Am Acad Dermatol 1987; 16: 688–695PubMedCrossRef

37.

Olsen E., Weiner M.S. Topical minoxidil in male pattern hair loss: effects of discontinuation of treatment. J Am Acad Dermatol 1987; 17: 97–101PubMedCrossRef

38.

Price V.H., Menefee E. Quantitative estimation of hair growth. I. Androgenetic alopecia in women: effect of minoxidil. J Invest Dermatol 1990; 95: 683–687PubMedCrossRef

39.

Diani A., Mulholland M.J., Shull K.L., et al. Hair growth effects of oral administration of finasteride, a steroid 5 alpha reductase inhibitor, alone and in combination with topical minoxidil in the balding stump-tailed macaque. J Clin Endocrinol Metab1992; 74: 345–350CrossRef

40.

Canadian Pharmacists Association. Monography. Compendium of pharmaceuticals and specialties (CPS). 34th Ed. Ottawa, Canada: Canadian Pharmacists Association, 1999

41.

Katz H.I., Hien N.T., Prawer S.E. Long-term efficacy of topical minoxidil in male pattern baldness. J Am Acad Dermatol 1987; 16 (3): 711–718PubMedCrossRef

42.

Ebsser H., Muller E. Allergic contact dermatitis from minoxidil. Contact Dermatitis1995; 32: 316–317CrossRef

43.

Kaufman K. Androgen metabolism as it affects hair growth in androgenetic alopecia.Dermatol Clin 1996; 14: 697–711PubMedCrossRef

44.

Kaufman K. Clinical studies on the effects of oral finasteride, a type II 5 alpha reductase inhibitor, on scalp hair in men with male pattern baldness. In: Van Neste D., Randall V., editors. Hair research for the next millenium. Amsterdam: Elsevier Science, 1996: 363

45.

Gormley G., Stoner E., Bruskewitz R., et al. The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med 1992; 327: 1185–1191PubMedCrossRef

46.

Stoner E. The clinical development of 5 alpha reductase inhibitor, finasteride. J Steroid Biochem Mol Biol 1990; 37: 375–378PubMedCrossRef

47.

Dallob A., Sadick N., Unger W., et al. The effects of finasteride, a 5 alpha-reductase inhibitor, on scalp skin testosterone and dihydroterstosterone concentrations in patients with male pattern baldness. J Clin Endocrinol Metab 1994; 79: 703–706PubMedCrossRef

48.

Drake L., Hordinsky M., Fiedler V., et al. The effects of finasteride on scalp skin and serum androgen levels in male with androgenetic alopecia. J Am Acad Dermatol1999; 41 (4): 550–554

49.

Leyden J., Dunlop F., Miller B., et al. Finasteride in the treatment of male with frontal male pattern hair loss. J Am Acad Dermatol 1999; 40 (6): 930–937PubMedCrossRef

50.

Kaurman K. Treatment with finasteride 1 mg per day in men with male pattern hair loss. Australas J Dermatol 1997; 38: 20

51.

Waldstreicher J. The effects of finasteride in men with frontal male pattern hair loss. Australas J Dermatol 1997; 38: 101CrossRef

52.

Roberts J., Hordinsky M.K., Olsen E.A., et al. The effects of finasteride on post-menopausal women with androgenetic alopecia [abstract]. Hair Workshop; 1998 May 2–3: Brussels: 16–17

53.

Overstreet J.W., Fuh V.L., Gould J., et al. Chronic treatment with finasteride daily does not affect spermatogenesis or semen production in young men. J Urol 1999 Oct; 162 (4): 1295–1300PubMedCrossRef

54.

Matzkin H., Barak M., Braf Z. Effect of finasteride on free and total serum prostate specific antigen in men with benign prostatic hypertrophy. Br J Urol 1996; 78: 405–408PubMedCrossRef

55.

Hammerstein J., Meckies J., Leo-Rossberg I., et al. Use of cyproterone acetate in the treatment of acne, hirsutism and virilism. J Steroid Biochem Mol Biol 1975; 6: 827–836

56.

Namer M. Clinical applications of antiandrogens. J Steroid Biochem Mol Biol1988; 31: 719–729

57.

Shaw J. Antiandrogen therapy in dermatology. Int J Dermatol 1996; 35 (11): 770–778PubMedCrossRef

58.

Dawber R.P.R., Sonnex T., Ralfs I. Oral antiandrogen treatment of common baldness in women. Br J Dermatol 1982; 107 Suppl. 22: 20–23

59.

Ekoe J., Burckhardt P., Ruedi B. Treatment of hirsutism, acne and alopecia with cyproterone acetate. Dermatologica 1980; 160: 398–404PubMedCrossRef

60.

Mortimer C., Rushton H., James K. Effective medical treatment for common baldness in women. Clin Exp Dermatol 1984; 9: 342–350PubMedCrossRef

61.

Neumann F. Pharmacology and potential use of cyproterone acetate. Horm Metab Res 1977; 9: 1–13PubMedCrossRef

62.

Simpson N. The management of androgenetic alopecia in women. J Dermatol Treatment 1989; 1: 107–113CrossRef

63.

Corbol P., Michard A., Minard J., et al. Antiandrogenic effect of spironolactone: mechanism of action. Endoctinology 1975; 97: 52–58CrossRef

64.

Lobo R.A., Shoupe D., Serafini P., et al. the effects of two doses of spironolactone on serum androgens and anagen hair in hirsute women. Fertil Steril 1985; 43: 200–205PubMed

65.

Loriaux D. Spironolactone and endocrine dysfunction (NIH conference). Ann Intern Med 1976; 85: 630

66.

Burke B., Cunliffe W. Oral spironolactone therapy for female patients with acne, hirsutism or androgenic alopecia. Br J Dermatol 1985; 11 (1): 124–125CrossRef

67.

Rushton D. Quantitative assessment of spironolactone treatment in women with diffuse androgen-dependent alopecia. J Socv Cosmet Chem 1991; 42: 317

68.

Elias P. Epidermal effects of retinoids: supramolecular observations and clinical implications. J Am Acad Dermatol 1986; 15: 797–809PubMedCrossRef

69.

Sporn M., Roberts A., Roche N., et al. Mechanism of action of retinoids. J Am Acad Dermatol 1986; 15: 756–764PubMedCrossRef

70.

Bazzano G., Terezakis N., Galen W. Topical tretinoin for hair growth promotion. J Am Acad Dermatol 1986; 15 (Pt 2): 880–883, 890-3PubMedCrossRef

Titel: Management of Androgenetic Alopecia
verfasst von: Chantal Bolduc
Dr Jerry Shapiro
Publikationsdatum: 01.05.2000
Verlag: Springer International Publishing
Erschienen in: American Journal of Clinical Dermatology / Ausgabe 3/2000
Print ISSN: 1175-0561
Elektronische ISSN: 1179-1888
DOI: https://doi.org/10.2165/00128071-200001030-00002

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

22.04.2024 | DGIM 2024 | Nachrichten

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Management of Androgenetic Alopecia

Abstract

Leitlinien kompakt für die Dermatologie

Neu im Fachgebiet Dermatologie

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Vitiligo: Prävalenz steigt und viele Erkrankte werden spät behandelt

Update Dermatologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2000

Verrucas

Drug-Induced Psoriasis

Topical Metronidazole

Acne Variants

Dermatoses of the Feet

Actinic Keratosis

Leitlinien kompakt für die Dermatologie

Neu im Fachgebiet Dermatologie

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Vitiligo: Prävalenz steigt und viele Erkrankte werden spät behandelt

Update Dermatologie